Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Gunhild Keller-von Amsberg & Steffen Koschmieder. (2013) Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia. OncoTargets and Therapy 6, pages 99-106.
Read now
Read now
Gunhild Keller-von Amsberg & Philippe Schafhausen. (2013) Bosutinib in the management of chronic myelogenous leukemia. Biologics: Targets and Therapy 7, pages 115-122.
Read now
Read now
Gunhild Keller-v.Amsberg & Tim H Brümmendorf. (2012) Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia. Expert Review of Anticancer Therapy 12:9, pages 1121-1127.
Read now
Read now
Alexander Pintzas, Boris Zhivotovsky, Paul Workman, Paul A. Clarke, Spiros Linardopoulos, Jean-Claude Martinou, Juan Carlos Lacal, Sylvie Robine, George Nasioulas & Ladislav Andera. (2012) Sensitization of (colon) cancer cells to death receptor related therapies. Cancer Biology & Therapy 13:7, pages 458-466.
Read now
Read now
Rüdiger Hehlmann, Susanne Jung-Munkwitz & Susanne Saußele. (2011) Treatment of chronic myeloid leukemia when imatinib fails. Expert Opinion on Pharmacotherapy 12:2, pages 269-283.
Read now
Read now
Ruriko Tanaka & Shinya Kimura. (2008) Abl tyrosine kinase inhibitors for overriding Bcr–Abl/T315I: from the second to third generation. Expert Review of Anticancer Therapy 8:9, pages 1387-1398.
Read now
Read now
Articles from other publishers (27)
Elena Porcù, Francesca Maule, Lorenzo Manfreda, Elena Mariotto, Silvia Bresolin, Alice Cani, Roberta Bortolozzi, Alessandro Della Puppa, Diana Corallo, Giampietro Viola, Elena Rampazzo & Luca Persano. (2023) Identification of Homoharringtonine as a potent inhibitor of glioblastoma cell proliferation and migration. Translational Research 251, pages 41-53.
Crossref
Crossref
Jingrong Zhao, Zhelin Li, Ruchira Puri, Kelvin Liu, Israel Nunez, Liang Chen & Sika Zheng. (2022) Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay. Molecular Therapy - Nucleic Acids 27, pages 304-318.
Crossref
Crossref
Rhythm Bharti & Sandeep Kumar Shukla. (2021) Molecules against Covid-19: An in silico approach for drug development. Journal of Electronic Science and Technology 19:1, pages 100095.
Crossref
Crossref
Imlimaong Aier & Pritish Kumar Varadwaj. 2021. Molecular Docking for Computer-Aided Drug Design. Molecular Docking for Computer-Aided Drug Design
313
336
.
David J. Newman & Gordon M. Cragg. (2020) Plant Endophytes and Epiphytes: Burgeoning Sources of Known and “Unknown” Cytotoxic and Antibiotic Agents?. Planta Medica 86:13/14, pages 891-905.
Crossref
Crossref
Zhanxia Zhang, Wei Cheng, Yongfu Pan & Lijun Jia. (2020) An anticancer agent-loaded PLGA nanomedicine with glutathione-response and targeted delivery for the treatment of lung cancer. Journal of Materials Chemistry B 8:4, pages 655-665.
Crossref
Crossref
Sumana Saha & Tapan Kumar Giri. (2019) Breaking the Barrier of Cancer through Papaya Extract and their Formulation. Anti-Cancer Agents in Medicinal Chemistry 19:13, pages 1577-1587.
Crossref
Crossref
C.M. Nijenhuis, L. Lucas, H. Rosing, J.H.M. Schellens, J.H. Beijnen, S.H. Gorman, S.M. Burke, D.A. Campbell, M.W. Chapple, T.H. Yousey & D.E. Mulvana. (2015) Validation of high-performance liquid chromatography–tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4′‑des-methyl and cephalotaxine metabolites in human plasma and urine. Journal of Chromatography B 1002, pages 152-159.
Crossref
Crossref
Akihiro Watari, Maki Hashegawa, Kiyohito Yagi & Masuo Kondoh. (2015) Homoharringtonine increases intestinal epithelial permeability by modulating specific claudin isoforms in Caco-2 cell monolayers. European Journal of Pharmaceutics and Biopharmaceutics 89, pages 232-238.
Crossref
Crossref
Shinsaku TAKAYAMA, Toshiaki UEMATSU & Motomu AKITA. (2014) Effect of Light Condition on Growth and Alkaloid Production in Japanese Plum-yew. Shokubutsu Kankyo Kogaku 26:1, pages 25-29.
Crossref
Crossref
Michael S Mathisen, Hagop M Kantarjian, Jorge Cortes, Farhad Ravandi & Elias J Jabbour. (2013) Novel treatment options for acute myelocytic leukemia. Clinical Investigation 3:10, pages 979-990.
Crossref
Crossref
Elias J. Jabbour, Jorge E. Cortes & Hagop M. Kantarjian. (2013) Resistance to Tyrosine Kinase Inhibition Therapy for Chronic Myelogenous Leukemia: A Clinical Perspective and Emerging Treatment Options. Clinical Lymphoma Myeloma and Leukemia 13:5, pages 515-529.
Crossref
Crossref
N. Daver, A. Vega-Ruiz, H.M. Kantarjian, Z. Estrov, A. Ferrajoli, S. Kornblau, S. Verstovsek, G. Garcia-Manero & J.E. Cortes. (2013) A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. European Journal of Cancer Care 22:5, pages 605-611.
Crossref
Crossref
Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth & J. Robert Merritt. 2013.
471
546
.
Mariano G. Cárdenas, Viviana C. Blank, Mariel N. Marder & Leonor P. Roguin. (2012) 2′-Nitroflavone induces apoptosis and modulates mitogen-activated protein kinase pathways in human leukaemia cells. Anti-Cancer Drugs 23:8, pages 815-826.
Crossref
Crossref
E K Allan, T L Holyoake, A R Craig & H G Jørgensen. (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 25:6, pages 985-994.
Crossref
Crossref
Vinayak Hegde, Marc Campitelli, Ronald J. Quinn & David Camp. (2011) Synthesis of novel molecular probes inspired by harringtonolide. Organic & Biomolecular Chemistry 9:12, pages 4570.
Crossref
Crossref
C. Monneret. (2010) Impact actuel des produits naturels sur la découverte de nouveaux médicaments anticancéreux. Annales Pharmaceutiques Françaises 68:4, pages 218-232.
Crossref
Crossref
Melissa Pires de Lima, Luciana Farhat Hilst, Fernanda Vanessa Rechinbach Mattana, Cid Aimbiré de Moraes Santos & Almeriane Maria Weffort-Santos. (2010) Alkaloid-rich fraction of Himatanthus lancifolius contains anti-tumor agents against leukemic cells. Brazilian Journal of Pharmaceutical Sciences 46:2, pages 273-280.
Crossref
Crossref
S A Bright, A M McElligott, J W O'Connell, L O'Connor, P Carroll, G Campiani, M W Deininger, E Conneally, M Lawler, D C Williams & D M Zisterer. (2010) Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. British Journal of Cancer 102:10, pages 1474-1482.
Crossref
Crossref
G. Vignir Helgason, Graham A. R. Young & Tessa L. Holyoake. (2010) Targeting Chronic Myeloid Leukemia Stem Cells. Current Hematologic Malignancy Reports 5:2, pages 81-87.
Crossref
Crossref
Farouk Berhal, Joëlle Pérard-Viret & Jacques Royer. (2010) Stereoselective synthesis of enantiopure analogues of (−)-cephalotaxine. Tetrahedron: Asymmetry 21:3, pages 325-332.
Crossref
Crossref
Ah-Reum Han, Ye Deng, Yulin Ren, Li Pan & A. Douglas Kinghorn. 2010. Dietary Components and Immune Function. Dietary Components and Immune Function
317
333
.
Zhonghua Liu, Qizhen Du, Kuiwu Wang, Lili Xiu & Guanglei Song. (2009) Completed preparative separation of alkaloids from Cephaltaxus fortunine by step-pH-gradient high-speed counter-current chromatography. Journal of Chromatography A 1216:22, pages 4663-4667.
Crossref
Crossref
Jason A. Smith, Peter P. Molesworth & John H. Ryan. 2009.
491
530
.
Farouk Berhal, Sébastien Tardy, Joëlle Pérard-Viret & Jacques Royer. (2009)
Synthesis of Optically Active Monoacid Side-Chains of
Cephalotaxus
Alkaloids
. European Journal of Organic Chemistry 2009:3, pages 437-443.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:4, pages 253-260.
Crossref
Crossref